Allergan plc (NYSE:AGN) Stock Position Lifted by Buckingham Asset Management LLC
Buckingham Asset Management LLC lifted its holdings in Allergan plc (NYSE:AGN) by 2.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,664 shares of the company’s stock after purchasing an additional 52 shares during the quarter. Buckingham Asset Management LLC’s holdings in Allergan were worth $472,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Wealth Quarterback LLC bought a new position in shares of Allergan in the fourth quarter worth $25,000. Golden State Wealth Management LLC bought a new position in shares of Allergan in the first quarter worth $25,000. WASHINGTON TRUST Co bought a new position in shares of Allergan in the first quarter worth $25,000. Paragon Capital Management LLC bought a new position in Allergan during the first quarter valued at about $30,000. Finally, Ellevest Inc. boosted its stake in Allergan by 233.3% during the first quarter. Ellevest Inc. now owns 180 shares of the company’s stock valued at $32,000 after buying an additional 126 shares in the last quarter. 83.91% of the stock is owned by institutional investors.
Several research analysts recently weighed in on the company. Cfra cut Allergan from a “buy” rating to a “hold” rating in a research note on Wednesday, March 25th. Wells Fargo & Co cut Allergan from an “overweight” rating to an “equal weight” rating and set a $198.00 target price for the company. in a research note on Wednesday, January 22nd. SunTrust Banks cut Allergan from a “buy” rating to a “hold” rating and raised their target price for the company from $191.00 to $193.00 in a research note on Tuesday, April 21st. Finally, ValuEngine raised Allergan from a “sell” rating to a “hold” rating in a report on Tuesday, March 24th. Fourteen investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $183.73.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, April 16th will be paid a $0.74 dividend. This represents a $2.96 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, April 15th. Allergan’s dividend payout ratio is currently 16.78%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Read More: What are Bollinger Bands?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.